연구성과로 돌아가기

2021 연구자 정보 (725 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Kim, Bum Jun
(Kim, BJ) ⓘ 		Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Coll Med, Anyang Si, Gyeonggi Do, South Korea ⓘ
ⓘ 		0000-0003-2360-5160
kim, bum jun ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr; ⓘ
Kim, Dong Sook
(Kim, DS) ⓘ 		Hlth Insurance Review & Assessment Serv, Review & Assessment Res Dept, Wonju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr; ⓘ
Kim, Hyeong Su
(Kim, HS) ⓘ 		Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Coll Med, Seoul, South Korea ⓘ GWR-2904-2022
Kim, Hyeongsu ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr; ⓘ
Kim, In-Ho
(Kim, IH) ⓘ 		Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
Catholic Univ Korea, Coll Med, Dept Internal Med, Div Med Oncol,Seoul St Marys Hosp, Seoul, South Korea
Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea ⓘ 		JWP-3629-2024
JXL-8219-2024
Kim, Jin Il
Kim, Sung-Bae ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
[JCR상위 43.9] 2020 Korean guidelines for the management of metastatic prostate cancer ⓘ 		SCIE ⓘ 2.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		fhdzang@hallym.or.kr;
ykkang@amc.seoul.kr;
cymed@cnu.ac.kr; ⓘ
Kim, Seung Tae
(Kim, ST) ⓘ 		Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.5] Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
[JCR상위 0.7] ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma ⓘ 		SCIE ⓘ 0.7 ONCOLOGY
MULTIDISCIPLINARY SCIENCES ⓘ 		jsheo@skku.edu;oncopark@skku.edu;
twkimmd@amc.seoul.kr;shivam@gene.com; ⓘ
Lee, Jeeyun
(Lee, JY) ⓘ 		Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Dept Intelligence Precis Healthcare Convergence, Sch Med, Suwon, South Korea ⓘ 		C-9646-2011
Lee, Jee ⓘ
ⓘ 		[JCR상위 32.5] Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
[JCR상위 0.7] ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma ⓘ 		SCIE ⓘ 0.7 ONCOLOGY
MULTIDISCIPLINARY SCIENCES ⓘ 		jsheo@skku.edu;oncopark@skku.edu;
twkimmd@amc.seoul.kr;shivam@gene.com; ⓘ
Oh, So Yeon
(Oh, SY) ⓘ 		Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea ⓘ GNM-9624-2022
Oh, So Yeon ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr; ⓘ
Park, Joon Oh
(Park, JO) ⓘ 		교신저자 Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Div Hematol Oncol, 81 Irwon Ro, Seoul 06351, South Korea ⓘ
ⓘ 		0000-0001-6502-2612
Park, Joon Oh ⓘ 		[JCR상위 32.5] Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer ⓘ SCIE ⓘ 32.5 ONCOLOGY ⓘ jsheo@skku.edu;oncopark@skku.edu; ⓘ
Park, Se Hoon
(Park, SH) ⓘ 		Sungkyunkwan Univ, Dept Med, Div Hematol Oncol, Samsung Med Ctr, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea ⓘ 		GMX-1199-2022
Park, Se Hoon ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
[JCR상위 43.9] 2020 Korean guidelines for the management of metastatic prostate cancer ⓘ 		SCIE ⓘ 2.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		fhdzang@hallym.or.kr;
cymed@cnu.ac.kr; ⓘ
Park, Young Suk
(Park, YS) ⓘ 		Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
Seoul Natl Univ, Dept Surg, Bundang Hosp, Seongnam, South Korea ⓘ 		AAV-3491-2020
B-4634-2014
park, youngsuk
Park, Sun-Young ⓘ 		0000-0002-6352-9759
Park, Young Suk ⓘ 		[JCR상위 32.5] Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
[JCR상위 72.5] Bariatric surgery versus medical therapy in Korean obese patients: prospective multicenter nonrandomized controlled trial (KOBESS trial) ⓘ 		SCIE ⓘ 32.5 ONCOLOGY
SURGERY ⓘ 		jsheo@skku.edu;oncopark@skku.edu;
gshur@inha.ac.kr; ⓘ
Shin, Sang Hyun
(Shin, SH) ⓘ 		Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.5] Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer ⓘ SCIE ⓘ 32.5 ONCOLOGY ⓘ jsheo@skku.edu;oncopark@skku.edu; ⓘ
Sym, Sun Jin
(Sym, SJ) ⓘ 		Gachon Univ Gil Hosp, Dept Internal Med, Div Hematol & Oncol, Incheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr; ⓘ
Zang, Dae Young
(Zang, DY) ⓘ 		교신저자 Hallym Univ, Dept Internal Med, Hallym Univ Sacred Heart Hosp, Coll Med, 22 Gwanpyeong Ro 170 Beongil Dongan Gu, Anyang Si 14068, Gyeonggi Do, South Korea
Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.5] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer ⓘ 		SCIE ⓘ 2.2 ONCOLOGY ⓘ fhdzang@hallym.or.kr;
ykkang@amc.seoul.kr; ⓘ
Avramov, P. V.
(Avramov, PV) ⓘ 		교신저자 Kyungpook Natl Univ, Dept Chem, Daugu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 32.7] Migration of Excitation Energy in Furocoumarins ⓘ SCIE ⓘ 32.7 CHEMISTRY, MULTIDISCIPLINARY ⓘ tchon@phys.tsu.ru;paul.avramov@gmail.com; ⓘ
Bocharnikova, E. N.
(Bocharnikova, EN) ⓘ 		Tomsk State Univ, Dept Phys, Lab Photophys & Photochem Mol, Tomsk, Russia ⓘ AAF-2312-2021
Bocharnikova, Elena ⓘ 		0000-0002-9412-7154
Bocharnikova, Elena ⓘ 		[JCR상위 32.7] Migration of Excitation Energy in Furocoumarins ⓘ SCIE ⓘ 32.7 CHEMISTRY, MULTIDISCIPLINARY ⓘ tchon@phys.tsu.ru;paul.avramov@gmail.com; ⓘ
페이지 이동: